RAMM Pharma

RAMM Pharma Capital Intensity

The Capital Intensity Ratio of RAMM Pharma (RAMM.CN) as of Nov 2, 2026 is 275.84 %. In the previous year, Capital Intensity Ratio was 385.74 % — a change of -28.49% (lower).

Capital Intensity

275.84 %

YoY

-28.49%

Last updated:

Capital Intensity Ratio of RAMM Pharma is 2025 275.84 % . Capital Intensity Ratio of RAMM Pharma was 2024 385.74 % . It decreases by -28.49% lower compared to the previous year.

The RAMM Pharma Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
83.03 CAD
Jan 1, 2019
760.81 CAD
Jan 1, 2020
682.76 CAD
Jan 1, 2021
1,450.61 CAD
Jan 1, 2022
1,008.52 CAD
Jan 1, 2023
637.68 CAD
Jan 1, 2024
385.74 CAD
Jan 1, 2025
275.84 CAD
The RAMM Pharma Capital Intensity history
YEARCapital IntensityYoY
275.84 %-28.49%
385.74 %-39.51%
637.68 %-36.77%
1,008.52 %-30.48%
1,450.61 %+112.46%
682.76 %-10.26%
760.81 %+816.30%
83.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

Capital Intensity Ratio of RAMM Pharma is 275.84 % in 2025.

Capital Intensity Ratio of RAMM Pharma changed from 385.74 % to 275.84 %, representing a -28.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's RAMM Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — RAMM Pharma

All Key Metrics — RAMM Pharma